search
Back to results

Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy (APT)

Primary Purpose

Pleural Effusion, Pleurisy, Empyema

Status
Completed
Phase
Phase 4
Locations
India
Study Type
Interventional
Intervention
Cefazolin
saline
Sponsored by
Postgraduate Institute of Medical Education and Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pleural Effusion focused on measuring thoracoscopy, pleuroscopy, antibiotic prophylaxis, pleural effusion

Eligibility Criteria

12 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥12 years
  2. Medical thoracoscopy being performed for a pleural effusion for any of the three indications: diagnosis, pleurodesis, or adhesiolysis

Exclusion Criteria:

  1. Age ≥80 years
  2. Pao2/FIO2< 300;
  3. Hemodynamic instability
  4. Myocardial infarction or unstable angina in the last 6 wk
  5. Lack of pleural space due to adhesions
  6. Uncorrected coagulopathy
  7. Failure to provide informed consent
  8. Patients already taking any antibiotic due to any reason

Sites / Locations

  • PGIMER

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Cefazolin

saline

Arm Description

A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.

100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.

Outcomes

Primary Outcome Measures

Efficacy as assessed by occurrence of wound infection or pleural space infection
(a) Occurrence of wound infection as indicated by development of a purulent discharge from the surgical site or (b) pleural space infection as indicated by development of purulence, fall in sugar levels or gram's stain or culture positivity in the pleural fluid drained by the chest tube on the side of the procedure.

Secondary Outcome Measures

Safety as assessed by adverse effects
Adverse effects arising as a result of the antibiotic administered

Full Information

First Posted
May 9, 2015
Last Updated
January 16, 2017
Sponsor
Postgraduate Institute of Medical Education and Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02446782
Brief Title
Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy
Acronym
APT
Official Title
A Study to Evaluate the Efficacy and Safety of a Single Dose of an Injectable Antibiotic for the Prophylaxis of Surgical Site and Pleural Space Infection After Medical Thoracoscopy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Postgraduate Institute of Medical Education and Research

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective study to assess the efficacy and safety of a single dose of cefazolin 2g IV for the prophylaxis of surgical site and pleural space infections in patients undergoing medical thoracoscopy.
Detailed Description
This is a prospective randomized study to assess the efficacy and safety of a single dose of cefazolin 2g IV for the prophylaxis of surgical site and pleural space infections during medical thoracoscopy. Consecutive patients who are planned to undergo a medical thoracoscopy (rigid or semirigid) will be enrolled in the study if they satisfy the inclusion and exclusion criteria. One hundred patients will be randomized in 1:1 ratio to receive either of the following: (a) A single dose of intravenous cefazolin 2 gms dissolved in 100 mL of normal saline administered over 10 minutes, between 15 and 30 minutes before the incision, OR (b) 100 mL normal saline administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. Thoracoscopy will be performed in the bronchoscopy suite on a spontaneously breathing subject (fasting for 8 h) under conscious sedation (using midazolam, pentazocine, and tramadol) observing complete aseptic precautions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pleural Effusion, Pleurisy, Empyema
Keywords
thoracoscopy, pleuroscopy, antibiotic prophylaxis, pleural effusion

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cefazolin
Arm Type
Experimental
Arm Description
A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
Arm Title
saline
Arm Type
Placebo Comparator
Arm Description
100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
Intervention Type
Drug
Intervention Name(s)
Cefazolin
Other Intervention Name(s)
Clindamycin
Intervention Description
Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
Intervention Type
Other
Intervention Name(s)
saline
Intervention Description
100 mL normal saline 15-30 minutes before the start of the procedure
Primary Outcome Measure Information:
Title
Efficacy as assessed by occurrence of wound infection or pleural space infection
Description
(a) Occurrence of wound infection as indicated by development of a purulent discharge from the surgical site or (b) pleural space infection as indicated by development of purulence, fall in sugar levels or gram's stain or culture positivity in the pleural fluid drained by the chest tube on the side of the procedure.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Safety as assessed by adverse effects
Description
Adverse effects arising as a result of the antibiotic administered
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥12 years Medical thoracoscopy being performed for a pleural effusion for any of the three indications: diagnosis, pleurodesis, or adhesiolysis Exclusion Criteria: Age ≥80 years Pao2/FIO2< 300; Hemodynamic instability Myocardial infarction or unstable angina in the last 6 wk Lack of pleural space due to adhesions Uncorrected coagulopathy Failure to provide informed consent Patients already taking any antibiotic due to any reason
Facility Information:
Facility Name
PGIMER
City
Chandigarh
ZIP/Postal Code
160012
Country
India

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy

We'll reach out to this number within 24 hrs